Humira (adalimumab) Letter of Medical Necessity
Humira (adalimumab) prior authorization denials are among the most common in specialty pharmacy. Most denials are reversible with a properly written Letter of Medical Necessity that addresses step therapy, prior treatment failures, and payer-specific medical policy criteria.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● plaque psoriasis
- ● Crohn's disease
- ● ulcerative colitis
- ● hidradenitis suppurativa
- ● uveitis
Why Humira Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy not completed (failed methotrexate or other csDMARDs)
- 2. Diagnosis not adequately documented (missing ICD-10 specificity)
- 3. Biosimilar (Amjevita, Cyltezo, Hadlima) preferred on formulary
- 4. Lab work or TB screening not on file
- 5. Quantity limit exceeded
What to Include in a Humira Letter of Medical Necessity
A successful Humira LMN should document the patient's confirmed diagnosis with ICD-10 specificity, prior conventional therapy trials with documented inadequate response or intolerance, baseline disease activity (e.g., DAS28, PASI, HBI), TB screening, and the clinical rationale for selecting adalimumab over preferred alternatives.
Key clinical evidence to cite:
- ✓ Multiple randomized controlled trials demonstrating efficacy across approved indications
- ✓ ACR, AAD, and AGA guideline endorsement for moderate-to-severe disease
- ✓ Long-term safety registry data (>20 years post-approval)
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 AGA 2020 IBD Guidelines
Humira Prior Authorization Criteria
Standard criteria across major US payers for Humira. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy not completed (failed methotrexate or other csDMARDs)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Humira
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Humira Prior Authorization FAQ
Why was my Humira prior authorization denied?
The most common denial reasons for Humira are: Step therapy not completed (failed methotrexate or other csDMARDs); Diagnosis not adequately documented (missing ICD-10 specificity); Biosimilar (Amjevita, Cyltezo, Hadlima) preferred on formulary; Lab work or TB screening not on file; Quantity limit exceeded.
What should a Humira Letter of Medical Necessity include?
A successful Humira LMN should document the patient's confirmed diagnosis with ICD-10 specificity, prior conventional therapy trials with documented inadequate response or intolerance, baseline disease activity (e.g., DAS28, PASI, HBI), TB screening, and the clinical rationale for selecting adalimumab over preferred alternatives.
Which payers cover Humira?
Humira is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.